A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Clinical trial NCT02588261 · TERMINATED
Trial details
- NCT number
- NCT02588261
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-11
- Primary completion
- 2017-12-21
- Enrollment
- 530
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.